Mainsail Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Mainsail Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$350K	Buy	+2,051	New	+$304K	0.14%	95

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mainsail Asset Management's NBIX Position: Q2 2026 in Review

Mainsail Asset Management opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 2,051 shares worth $350K. The stake represents 0.14% of the portfolio and ranks #95 among its holdings.

772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Mainsail Asset Management held 2,051 shares of Neurocrine Biosciences worth $350K as of Q2 2026.
Neurocrine Biosciences was a new Mainsail Asset Management position in Q2 2026.
Neurocrine Biosciences made up 0.14% of Mainsail Asset Management's portfolio in Q2 2026, its #95 holding.
772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Mainsail Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.